Orforglipron [Sublingual Tablets]

Description

Orforglipron Sublingual Tablets

Orforglipron is a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) antagonist under research for metabolic and appetite regulation in research models. It is provided in sublingual tablet form to enhance absorption and bioavailability via the oral mucosa.
The product is intended for laboratory research only and not for human consumption.

Available quantities:

• 6 mg per tablet, 90 ct / 540 mg – $200.98
• 12 mg per tablet, 90 ct / 1080 mg – $380.48

Chemical Properties

• Molecular Formula: C₃₀H₃₄F₂N₄O₄
• Molecular Weight: 554.61 g·mol⁻¹
• Synonyms: ORG-8186, GLP-1 receptor antagonist, Orforglipron
• IUPAC Name: (S)-N-(1-(3-(2,2-difluoroethyl)-5-methoxyphenyl)ethyl)-6-(2-methoxyethoxy)-4-(trifluoromethyl)pyrimidin-2-amine
• CAS Number: 2570627-87-0

What is the Working Mechanism of Orforglipron in Experimental Models?

Orforglipron functions primarily as a GLP-1 receptor antagonist, modulating pathways related to appetite, insulin secretion, and energy balance:

GLP-1 Receptor Antagonism:
In experimental models, Orforglipron binds to GLP-1 receptors in the pancreas and brain, inhibiting endogenous GLP-1 signaling. This pathway is critical for regulating glucose-dependent insulin secretion and appetite modulation.

Metabolic Regulation:
Preclinical research suggests that Orforglipron may influence gastric emptying rates and satiety signaling, potentially affecting weight management in animal models.

Glucose Homeostasis Modulation:
By regulating GLP-1 activity, Orforglipron may impact glucose-dependent insulin secretion in preclinical studies, providing a framework for studying hyperglycemia and metabolic disorders.

Neuroendocrine Effects:
Laboratory studies indicate potential central nervous system effects through modulation of hypothalamic appetite centers, suggesting a role in controlling food intake behavior.

Potential Research Benefits of Orforglipron Sublingual Tablets

• Investigational support for metabolic regulation and appetite control studies.
• May serve as a model compound for studying GLP-1 pathway inhibition.
• Could provide insights into energy balance, gastric motility, and glucose homeostasis mechanisms.
• May reduce postprandial insulin secretion in controlled experimental models.

Potential Side Effects Observed in Preclinical Studies

• Gastrointestinal disturbances, including mild nausea or upset stomach.
• Possible fatigue or lethargy in animal studies.
• Occasional transient headaches in controlled laboratory environments.

Why choose RCDbio for Orforglipron Sublingual Tablets?

RCDbio provides research chemicals with third-party testing for quality and purity standards. We aim to be your trusted online source for this compound. In addition, we provide a quick and secure transaction experience to our buyers.

Disclaimer

Orforglipron Sublingual Tablets are intended exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, treat, cure, or prevent any disease. The Food and Drug Administration has not evaluated the statements on our website. By purchasing, you agree to our Terms and Conditions.